Serum proteomics hint at an early T-cell response and modulation of SARS-CoV-2-related pathogenic pathways in COVID-19-ARDS treated with Ruxolitinib

Serum proteomics hint at an early T-cell response and modulation of SARS-CoV-2-related pathogenic pathways in COVID-19-ARDS treated with Ruxolitinib

Background: Acute respiratory distress syndrome (ARDS) in corona virus disease 19 (COVID-19) is triggered by hyperinflammation, thus providing a rationale for immunosuppressive treatments. The Janus kinase inhibitor Ruxolitinib (Ruxo) has shown efficacy in severe and critical COVID-19. In this study...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Völkel, Sara, Tarawneh, Thomas S., Sacher, Laura, Bhagwat, Aditya M., Karim, Ihab, Mack, Hildegard I. D., Wiesmann, Thomas, Beutel, Gjörn, Hoyer, Joachim, Keller, Christian, Renz, Harald, Burchert, Andreas, Neubauer, Andreas, Graumann, Johannes, Skevaki, Chrysanthi, Mack, Elisabeth K. M.
Médium: Článek
Jazyk:angličtina
Vydáno: Philipps-Universität Marburg 2023
Témata:
SARS-CoV-2
proteomics
COVID-19
Medizin
acute respiratory distress syndrome
Ruxolitinib
Medical sciences Medicine
On-line přístup:Plný text ve formátu PDF
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Publikationen im Open Access gefördert durch die UB

Podobné jednotky